Passive and active immunization against respiratory syncytial virus for the young and old

References

• Blount RE Jr., Morris JA, Savage RE. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Medicine.Society Exp Biol Med (New York, N.Y.). 1956;92(3):544–549.
   PubMed Web of Science ®Google Scholar
• Chanock R, Finberg L. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children. Am J Hyg. 1957;66(3):291–300.
   PubMed Web of Science ®Google Scholar
• Chanock R, Roizman B, Myers R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am J Hyg. 1957;66(3):281–290.
   PubMed Web of Science ®Google Scholar
• Mazur NI, Martinon-Torres F, Baraldi E, et al. Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respir Med. 2015;3(11):888–900.
   PubMed Web of Science ®Google Scholar
• Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89(4):422–434.
   PubMed Web of Science ®Google Scholar
• Kapikian AZ, Mitchell RH, Chanock RM, et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol. 1969;89(4):405–421.
   PubMed Web of Science ®Google Scholar
• Chin J, Magoffin RL, Shearer LA, et al. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol. 1969;89(4):449–463.
   PubMed Web of Science ®Google Scholar
• Fulginiti VA, Eller JJ, Sieber OF, et al. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol. 1969;89(4):435–448.
   PubMed Web of Science ®Google Scholar
• Sun J, Remmele RL Jr., Sanyal G. Analytical Characterization of an Oil-in-Water Adjuvant Emulsion. AAPS Pharmscitech. 2016.
   Web of Science ®Google Scholar
• Ngwuta JO, Chen M, Modjarrad K, et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med. 2015;7(309):309ra162.
   PubMed Web of Science ®Google Scholar
• Magro M, Mas V, Chappell K, et al. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci U S A. 2012;109(8):3089–3094.
   PubMed Web of Science ®Google Scholar
• Schanzer DL, Langley JM, Tam TW. Role of influenza and other respiratory viruses in admissions of adults to Canadian hospitals. Influenza Other Respi Viruses. 2008;2(1):1–8.
   PubMed Web of Science ®Google Scholar
• Malloy AM, Falsey AR, Ruckwardt TJ. Consequences of immature and senescent immune responses for infection with respiratory syncytial virus. Curr Top Microbiol Immunol. 2013;372:211–231.
   PubMed Web of Science ®Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–2128.
   PubMed Web of Science ®Google Scholar
• Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545–1555.
   PubMed Web of Science ®Google Scholar
• Modjarrad K, Giersing B, Kaslow DC, et al. WHO consultation on respiratory syncytial virus vaccine development report from a world health organization meeting held on 23-24 march 2015. Vaccine. 2016;34(2):190–197.
   PubMed Web of Science ®Google Scholar
• Resch B, Eibisberger M, Morris N, et al. Respiratory syncytial virus- and influenza virus-associated hospitalizations in infants less than 12 months of age. Pediatr Infect Dis J. 2011;30(9):797–799.
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics ID. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. In: Pediatrics. United States: by the American Academy of Pediatrics; 2014. p. e620–638.
   Google Scholar
• Drysdale SB, Green CA, Sande CJ. Best practice in the prevention and management of paediatric respiratory syncytial virus infection. Ther Adv Infect Dis. 2016;3(2):63–71.
   PubMed Web of Science ®Google Scholar
• Lopez Bernal JA, Upton MN, Henderson AJ, et al. Lower respiratory tract infection in the first year of life is associated with worse lung function in adult life: prospective results from the Barry Caerphilly Growth study. Ann Epidemiol. 2013;23(7):422–427.
   PubMed Web of Science ®Google Scholar
• Escobar GJ, Masaquel AS, Li SX, et al. Persistent recurring wheezing in the fifth year of life after laboratory-confirmed, medically attended respiratory syncytial virus infection in infancy. BMC Pediatr. 2013;13:97-2431-2413-2497.
   PubMed Web of Science ®Google Scholar
• Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368(19):1791–1799.
   PubMed Web of Science ®Google Scholar
• Hall CB, Weinberg GA, Blumkin AK, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics. 2013;132(2):e341–348.
   PubMed Web of Science ®Google Scholar
• Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588–598.
   PubMed Web of Science ®Google Scholar
• Garcia CG, Bhore R, Soriano-Fallas A, et al. Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis. Pediatrics. 2010;126(6):e1453–1460.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Peterson DR, Falsey AR. Is clinical recognition of respiratory syncytial virus infection in hospitalized elderly and high-risk adults possible?. J Infect Dis. 2007;195(7):1046–1051.
   PubMed Web of Science ®Google Scholar
• Falsey AR, McElhaney JE, Beran J, et al. Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness. J Infect Dis. 2014.
   Web of Science ®Google Scholar
• Duncan CB, Walsh EE, Peterson DR, et al. Risk factors for respiratory failure associated with respiratory syncytial virus infection in adults. J Infect Dis. 2009;200(8):1242–1246.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352(17):1749–1759.
   PubMed Web of Science ®Google Scholar
• Fleming DM, Taylor RJ, Lustig RL, et al. Modelling estimates of the burden of Respiratory Syncytial virus infection in adults and the elderly in the kingdom UK. BMC Infect Dis. 2015. 15:443.
   PubMed Web of Science ®Google Scholar
• Wheeler SM, Dotters-Katz S, Heine RP, et al. Maternal effects of respiratory syncytial virus infection during pregnancy. Emerg Infect Dis. 2015;21(11):1951–1955.
   PubMed Web of Science ®Google Scholar
• Hynicka LM, Ensor CR. Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients. Ann Pharmacother. 2012;46(4):558–566.
   PubMed Web of Science ®Google Scholar
• Beeler JA, van Wyke Coelingh K. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol. 1989;63(7):2941–2950.
   PubMed Web of Science ®Google Scholar
• Varga SM, Wissinger EL, Braciale TJ. The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+ T cell responses. J Immunol. 2000;165(11):6487–6495.
   PubMed Web of Science ®Google Scholar
• Haynes LM, Jones LP, Barskey A, et al. Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J Virol. 2003;77(18):9831–9844.
   PubMed Web of Science ®Google Scholar
• Polack FP, Teng MN, Collins PL, et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med. 2002;196(6):859–865.
   PubMed Web of Science ®Google Scholar
• McLellan JS, Chen M, Leung S, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013;340(6136):1113–1117.
   PubMed Web of Science ®Google Scholar
• McLellan JS, Yang Y, Graham BS, et al. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol. 2011;85(15):7788–7796.
   PubMed Web of Science ®Google Scholar
• Raghunandan R, Lu H, Zhou B, et al. An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization. Vaccine. 2014;32(48):6485–6492.
   PubMed Web of Science ®Google Scholar
• Glenn GM, Fries LF, Smith G, et al. Modeling maternal fetal RSV F vaccine induced antibody transfer in guinea pigs. Vaccine. 2015;33(47):6488–6492.
   PubMed Web of Science ®Google Scholar
• Glenn GM, Smith G, Fries L, et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine. 2013 Jan 7;31(3):524–532. doi: 10.1016/j.vaccine.2012.11.009. Epub 2012 Nov 12.
   PubMed Web of Science ®Google Scholar
• Fries L, Glenn GM. Novavax Investor and Analyst Presentation. Rockville, MD: Novavax. November 9, 2016.
   Google Scholar
• Lambert SL, Aslam S, Stillman E, et al. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models. Plos One. 2015;10(3):e0119509.
   PubMed Web of Science ®Google Scholar
• Patton K, Aslam S, Shambaugh C, et al. Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaques. Vaccine. 2015;33(36):4472–4478.
   PubMed Web of Science ®Google Scholar
• Falloon J, Ji F, Curtis C, et al. A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant. Vaccine. 2016;34(25):2847–2854.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Walsh EE, Capellan J, et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines–nonadjuvanted vaccine or vaccine adjuvanted with alum–given concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis. 2008;198(9):1317–1326.
   PubMed Web of Science ®Google Scholar
• Munoz FM, Piedra PA, Glezen WP. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine. 2003;21(24):3465–3467.
   PubMed Web of Science ®Google Scholar
• Graham BS, Modjarrad K, McLellan JS. Novel antigens for RSV vaccines. Curr Opin Immunol. 2015;35:30–38.
   PubMed Web of Science ®Google Scholar
• McLellan JS, Chen M, Joyce MG, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013;342(6158):592–598.
   PubMed Web of Science ®Google Scholar
• Langley JM, Aggarwal N, Toma A, et al. A randomized, controlled, observer-blind Phase I study of the safety and immunogenicity of a respiratory syncytial virus vaccine with or without alum adjuvant. J Infect Dis. 2017 Jan 1;215(1):24–33. doi: 10.1093/infdis/jiw453. Epub 2016 Sep 29.
   PubMed Web of Science ®Google Scholar
• Stewart-Jones GB, Thomas PV, Chen M, et al. A cysteine zipper stabilizes a pre-fusion f glycoprotein vaccine for respiratory syncytial virus. Plos One. 2015;10(6):e0128779.
   PubMed Web of Science ®Google Scholar
• Karron RA, Buchholz UJ, Collins PL. Live-attenuated respiratory syncytial virus vaccines. Curr Top Microbiol Immunol. 2013;372:259–284.
   PubMed Web of Science ®Google Scholar
• Wright PF, Karron RA, Belshe RB, et al. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine. 2007;25(42):7372–7378.
   PubMed Web of Science ®Google Scholar
• Collins PL, Hill MG, Camargo E, et al. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5ʹ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci U S A. 1995;92(25):11563–11567.
   PubMed Web of Science ®Google Scholar
• Belshe RB, Newman FK, Anderson EL, et al. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children. J Infect Dis. 2004;190(12):2096–2103.
   PubMed Web of Science ®Google Scholar
• Karron RA, Wright PF, Belshe RB, et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis. 2005;191(7):1093–1104.
   PubMed Web of Science ®Google Scholar
• Luongo C, Yang L, Winter CC, et al. Codon stabilization analysis of the “248” temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates. Vaccine. 2009;27(41):5667–5676.
   PubMed Web of Science ®Google Scholar
• Belshe RB, Van Voris LP, Mufson MA. Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial. J Infect Dis. 1982;145(3):311–319.
   PubMed Web of Science ®Google Scholar
• Malkin E, Yogev R, Abughali N, et al. Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age. Plos One. 2013;8(10):e77104.
   PubMed Web of Science ®Google Scholar
• Karron RA, Thumar B, Schappell E, et al. Attenuation of live respiratory syncytial virus vaccines is associated with reductions in levels of nasal cytokines. J Infect Dis. 2013;207(11):1773–1779.
   PubMed Web of Science ®Google Scholar
• Jin H, Zhou H, Cheng X, et al. Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo. Virology. 2000;273(1):210–218.
   PubMed Web of Science ®Google Scholar
• Karron RA, Luongo C, Thumar B, et al. A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children. Sci Transl Med. 2015;7(312):312ra175.
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Malkin E, Abughali N, et al. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatr Infect Dis J. 2012 Feb;31(2):109–114. doi: 10.1097/INF.0b013e31823386f1.
   PubMed Web of Science ®Google Scholar
• Widjojoatmodjo MN, Bogaert L, Meek B, et al. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats. Vaccine. 2015;33(41):5406–5414.
   PubMed Web of Science ®Google Scholar
• Green CA, Scarselli E, Sande CJ, et al. Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Sci Transl Med. 2015;7:(300), 300ra126.
   Web of Science ®Google Scholar
• Jordan E A randomized, single-blind, placebo-controlled phase 1 trial to evaluate the safety, tolerability and immunogenicity of the recombinant MVA-BN RSV vaccine in healthy adult subjects. RSV16 10th International Respiratory Syncytial Virus Symposium; Patagonia (Argentina). (Sept. 28–Oct. 1, 2016).
   Google Scholar
• Simister NE. Placental transport of immunoglobulin G. Vaccine. 2003;21(24):3365–3369.
   PubMed Web of Science ®Google Scholar
• Payakachat N, Hadden KB, Ragland D. Promoting Tdap immunization in pregnancy: associations between maternal perceptions and vaccination rates. Vaccine. 2016;34(1):179–186.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Nunes MC, Cutland CL. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med. 2014;371(24):2340.
   PubMed Web of Science ®Google Scholar
• Ogilvie MM, Vathenen AS, Radford M, et al. Maternal antibody and respiratory syncytial virus infection in infancy. J Med Virol. 1981;7(4):263–271.
   PubMed Web of Science ®Google Scholar
• Glezen WP, Paredes A, Allison JE, et al. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr. 1981;98(5):708–715.
   PubMed Web of Science ®Google Scholar
• Lamprecht CL, Krause HE, Mufson MA. Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J Infect Dis. 1976;134(3):211–217.
   PubMed Web of Science ®Google Scholar
• Chu HY, Steinhoff MC, Magaret A, et al. Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh. J Infect Dis. 2014;210(10):1582–1589.
   PubMed Web of Science ®Google Scholar
• Nyiro JU, Sande C, Mutunga M, et al. Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya. Vaccine. 2015;33(15):1797–1801.
   PubMed Web of Science ®Google Scholar
• Ding H, Black CL, Ball S, et al. Influenza vaccination coverage among pregnant women–United States, 2014-15 influenza season. MMWR Morb Mortal Wkly Rep. 2015;64(36):1000–1005.
   PubMed Web of Science ®Google Scholar
• Glenn GM, Fries LF, Thomas DN, et al. A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (f) nanoparticle vaccine in healthy women of childbearing age. J Infect Dis. 2016;213(3):411–422.
   PubMed Web of Science ®Google Scholar
• Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3):531–537.
   Web of Science ®Google Scholar
• O’Brien KL, Chandran A, Weatherholtz R, et al. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. Lancet Infect Dis. 2015;15(12):1398–1408.
   PubMed Web of Science ®Google Scholar
• Carbonell-Estrany X, Simoes EA, Dagan R, et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics. 2010;125(1):e35–51.
   PubMed Web of Science ®Google Scholar
• Sivapalasingam S, Perez-Caballero D, Houghton M, et al. Phase 1 study evaluating safety, tolerability, pharmacokinetics and immunogenicity of REGN2222 in healthy adults: an investigational human monoclonal RSV-F antibody for RSV prevention. Open Forum Infect Dis. 2015;2(suppl_1):912. doi: 10.1093/ofid/ofv133.628.
   Google Scholar
• Kwakkenbos MJ, Diehl SA, Yasuda E, et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat Med. 2010;16(1):123–128.
   PubMed Web of Science ®Google Scholar
• Robbie GJ, Criste R, Dall’acqua WF, et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother. 2013;57(12):6147–6153.
   PubMed Web of Science ®Google Scholar
• Yu XQ, Robbie GJ, Wu Y,, . Pharmacokinetics of MEDI4893, an investigational, extended-half-life, anti-staphylococcus aureus alpha-toxin human monoclonal antibody, in healthy adults. Antimicrob Agents Chemother. 2017;61:1.
   Web of Science ®Google Scholar
• Griffin MP, Khan AA, Esser MT, et al. Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults. Antimicrob Agents Chemother. 2017;61:3.
   Web of Science ®Google Scholar
• Simoes EA, Carbonell-Estrany X, Guilbert T, et al. Clinical endpoints for respiratory syncytial virus prophylaxis trials in infants and children in high-income and middle-income countries. Pediatr Infect Dis J. 2015;34(10):1086–1092.
   PubMed Web of Science ®Google Scholar
• Roberts JN, Graham BS, Karron RA, et al. Challenges and opportunities in RSV vaccine development: meeting report from FDA/NIH workshop. Vaccine. 2016;34(41):4843–4849.
   PubMed Web of Science ®Google Scholar
• McClure DL, Kieke BA, Sundaram ME, et al. Seasonal incidence of medically attended respiratory syncytial virus infection in a community cohort of adults >/=50 years old. Plos One. 2014;9:(7), e102586.
   Web of Science ®Google Scholar
• Falsey AR, Walsh EE. Respiratory syncytial virus infection in elderly adults. Drugs & Aging. 2005;22(7):577–587.
   PubMed Web of Science ®Google Scholar
• Feldman AS, He Y, Moore ML, et al. Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma. Am J Respir Crit Care Med. 2015;191(1):34–44.
   PubMed Web of Science ®Google Scholar
• Siezen CL, Bont L, Hodemaekers HM, et al. Genetic susceptibility to respiratory syncytial virus bronchiolitis in preterm children is associated with airway remodeling genes and innate immune genes. Pediatr Infect Dis J. 2009;28(4):333–335.
   PubMed Web of Science ®Google Scholar
• Singh AM, Moore PE, Gern JE, et al. Bronchiolitis to asthma: a review and call for studies of gene-virus interactions in asthma causation. Am J Respir Crit Care Med. 2007;175(2):108–119.
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Gibbs RL, Lehr MV, et al. Respiratory outcomes in high-risk children 7 to 10 years after prophylaxis with respiratory syncytial virus immune globulin. Am J Med. 2002;112(8):627–633.
   PubMed Web of Science ®Google Scholar
• Simoes EA, Carbonell-Estrany X, Rieger CH, et al. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. J Allergy Clin Immunol. 2010;126(2):256–262.
   PubMed Web of Science ®Google Scholar
• Yoshihara S, Kusuda S, Mochizuki H, et al. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants. Pediatrics. 2013;132(5):811–818.
   PubMed Web of Science ®Google Scholar
• Mochizuki H, Kusuda S, Okada K, et al. Palivizumab prophylaxis in preterm infants and subsequent recurrent wheezing: 6 year follow up study. Am J Respir Crit Care Med. 2017.
   Web of Science ®Google Scholar